3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Pathologic Complete Response
1
Neoplasms by Site
1
Neoplasms
1
Hemangiosarcoma
1
Head and Neck Neoplasms
1
Carcinoma, Squamous Cell
1
Breast Neoplasms
1
Interventions
Trastuzumab
5
Carboplatin
4
toripalimab
2
pertuzumab
2
pembrolizumab
2
Tretinoin
2
Paclitaxel
2
Immunotherapy
2
Drug Therapy
2
Doxorubicin
2
Docetaxel
2
Cytarabine
2
130-nm albumin-bound paclitaxel
2
zanidatamab
1
venetoclax
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
tislelizumab
1
temsirolimus
1
talazoparib
1
tagraxofusp
1
sarilumab
1
sargramostim
1
pyrotinib
1
pexidartinib
1
pazopanib
1
patritumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Pathologic Complete Response
×
patritumab
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled